#AS­CO21: Bris­tol My­ers takes home the win in 1st late-stage study for LAG-3 path­way, set­ting up a US fil­ing

When Bris­tol My­ers Squibb dropped win­ning late-stage da­ta for its an­ti-LAG-3 drug in March, the re­sults of­fered new hope for an im­mune check­point path­way that had long lagged be­hind its bet­ter-known cousins. Now, the drug­mak­er is rolling out hard num­bers on that win, and it looks very promis­ing for an even­tu­al com­bo ap­proval along­side Op­di­vo.

A com­bo of Bris­tol My­ers’ LAG-3 in­hibitor re­latlimab and PD-1 block­er Op­di­vo post­ed a pro­gres­sion-free sur­vival of 10.12 months in pa­tients with metasta­t­ic or un­re­sectable melanoma com­pared with 4.63 months for pa­tients on Op­di­vo alone, ac­cord­ing to da­ta from the Phase II/III REL­A­TIV­I­TY-047 study set to be pre­sent­ed at AS­CO in June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER